Ontology highlight
ABSTRACT:
SUBMITTER: Zhou P
PROVIDER: S-EPMC7501589 | biostudies-literature | 2020 Sep
REPOSITORIES: biostudies-literature
Zhou Ping P Wang Justin J Mishail Daniel D Wang Cun-Yu CY
Precision clinical medicine 20200831 3
Poly(ADP-ribose) polymerase inhibitors (PARPi) are a new class of agents with unparalleled clinical achievement for driving synthetic lethality in BRCA-deficient cancers. Recent FDA approval of PARPi has motivated clinical trials centered around the optimization of PARPi-associated therapies in a variety of BRCA-deficient cancers. This review highlights recent advancements in understanding the molecular mechanisms of PARP 'trapping' and synthetic lethality. Particular attention is placed on the ...[more]